Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Aug 1;21(8):2381-2388.
doi: 10.31557/APJCP.2020.21.8.2381.

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study

Arb-Aroon Lertkhachonsuk  1 , Prapaporn Suprasert  2 , Tarinee Manchana  3 , Thannaporn Kittisiam  4 , Nuttavut Kantathavorn  5   6 , Tharintorn Chansoon  7 , Surapan Khunamornpong  8 , Natkrita Pohthipornthawat  9 , Siriwan Tangjitgamol  10 , Taksa Luasiripanthu  6 , Chinachote Teerapakpinyo  11 , Shanop Shuangshot  12 , Nareenart Iemwimangsa  13 , Wasun Chantratita  13
Affiliations
Multicenter Study

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study

Arb-Aroon Lertkhachonsuk et al. Asian Pac J Cancer Prev. .

Abstract

Background and objective: Ovarian, fallopian tube, or primary peritoneal cancer patients with BRCA gene mutation have enhanced sensitivity to platinum-based regimens and PARP inhibitors. However, the knowledge regarding BRCA mutation in Thai patients is limited. This study aimed at identifying the prevalence and characteristics of somatic and germline BRCA 1 and 2 mutations in Thai patients with these cancers.

Materials and methods: The paraffin blocks of tumors with histology of high grade serous, high grade endometrioid, or clear cell carcinoma obtained between June 2016 and December 2017 were analyzedto evaluate BRCA mutation using next-generation sequencing system. Blood or normal tissue paraffin blocks of positive patients were further tested for germline BRCA mutation.

Results: Tissue paraffin blocks of 178 patients were collected but only 139 were analyzed. Positive BRCA mutation was identified in 24 patients (17.3%): BRCA1 in 13 cases, BRCA2 in 10 cases, and BRCA1 and 2 in the rest one. Germline mutation study in blood or normal tissue in 23 positive patients revealed BRCA mutation in 14 cases, BRCA1 in 8 cases and BRCA 2 in 6 cases. Overall, the prevalence of somatic and germline mutation was 6.5% (9 out of 138 patients) and 8.7% (14 out of 138 patients), respectively. The most common histology associated with BRCA mutation was high grade serous cancer (27.3%). No significant difference was found between patients with or without BRCA mutation in terms of stage, outcome, platinum status, and survival outcome.

Conclusion: BRCA mutation was demonstrated in less than 10% of Thai ovarian cancer patients. Higher rate of mutation was found in high grade serous cancer.<br />.

Keywords: BRCA mutation; Ovarian Cancer; fallopian tube cancer; peritoneal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression –Free Survival in Patients with and without Pathogenic BRCA Gene. Median progression free survival: Pathogenic BRCA gene = 31.8 months vs. non-pathogenic BRCA gene = 30 months; 2 year progression free survival : Pathogenic BRCA gene = 68.2% (95%CI 48.8-87.6% ) vs. non- Pathogenic BRCA gene = 59% (95% CI 49.6-68.4); Log rank test P = 0.43; CI = confidence interval
Figure 2
Figure 2
Overall Survival (OS) in Patients with and without Pathogenic BRCA Gene. Log rank test P = 0.077 2-yrs overall survival : non-pathogenic BRCA gene = 87.2%(95% CI 88.8-100%), pathogenic BRCA gene = 95% (95% CI 77.6-96.8%); CI = confidence interval
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. - PMC - PubMed
    1. Chao A, Chang TC, Lapke N, et al. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016;7:85529–41. - PMC - PubMed
    1. Dougherty BA, Lai Z, Hodgson DR, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8:43653–61. - PMC - PubMed
    1. da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo) 2018;73:e450s. - PMC - PubMed
    1. Einaga N, Yoshida A, Noda H, et al. Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PLoS One. 2017;12:e0176280. - PMC - PubMed

Publication types

MeSH terms